Biotechnology firm Biocon is foraying into the critical care segment aiming to provide treatment for hospital infections, including post surgical complications and trauma. There is a perceptible increase in hospital acquired infections with respect to critical care illnesses in
This often requires treatment with anti-infectives. Biocon's comprehensive care division has been set up to counter this growing challenge by providing affordable and specialised solutions to such patients. The company will introduce five new products in the initial phase of launch for the treatment of critical illnesses like septicemia and other acute hospital infections.
The new comprehensive care division will be the fifth division for the company, complementing the existing product portfolios in diabetology, oncology, nephrology and cardiology divisions.
crackcrack
